Cardiff Oncology Reports Q3 Earnings Beat on Revenue and EPS
Cardiff Oncology (CRDF) reported third-quarter financial results that exceeded analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of -$0.12, outperforming estimates by $0.02, while revenue reached $0.17 million, representing a 41.7% increase year-over-year and beating projections by $0.08 million. As of September 30, 2026, the company maintained a strong liquidity position with approximately $33.8 million in cash, cash equivalents, and short-term investments. The results reflect steady top-line growth despite ongoing net losses typical of clinical-stage biotechnology firms.
Tickers: $CRDF
Topics: cash position earnings beat revenue growth